Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.61 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.54 |
| ▸ | DPP3 | Q9NY33 | 3/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | MC3R | P41968 | 2/20 | 0.51 |
| ▸ | MC1R | Q01726 | 2/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461097 | 0.98 | CXCR4 (0.59) | CXCR4IL23RC5AR1DPP3MC4R | |
| SCHEMBL31001651 | 0.96 | CXCR4 (0.59) | CXCR4IL23RC5AR1DPP3NTSR2 | |
| SCHEMBL34461095 | 0.94 | CXCR4 (0.68) | CXCR4IL23RC5AR1NTSR2NTSR1 | |
| SCHEMBL34461077 | 0.94 | CXCR4 (0.58) | CXCR4IL23RC5AR1DPP3MC4R | |
| SCHEMBL34461103 | 0.92 | CXCR4 (0.66) | CXCR4IL23RC5AR1NTSR2NTSR1 | |
| SCHEMBL34461111 | 0.92 | DPP3 (0.56) | CXCR4IL23RC5AR1DPP3NTSR2 | |
| SCHEMBL34461090 | 0.89 | DPP3 (0.59) | CXCR4IL23RC5AR1DPP3MC4R | |
| SCHEMBL34461110 | 0.88 | DPP3 (0.53) | CXCR4IL23RC5AR1DPP3 | |
| SCHEMBL34461092 | 0.88 | CXCR4 (0.59) | CXCR4C5AR1DPP3NTSR2NTSR1 | |
| SCHEMBL34461114 | 0.86 | DPP3 (0.55) | CXCR4IL23RC5AR1DPP3MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024177909-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT IN SUBJECTS HAVING A FIBROTIC DISEASE USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | CXCR4 2538/4885IL23R 831/4885C5AR1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.